☰

Sevin Turcan - Publications

Affiliations: 
Biomedical Engineering Tufts University, Boston 
Tree Info Grants Similar researchers PubMed Report error

27/53 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Blanco-Carmona E, Narayanan A, Hernandez I, Nieto JC, Elosua-Bayes M, Sun X, Schmidt C, Pamir N, Özduman K, Herold-Mende C, Pagani F, Cominelli M, Taranda J, Wick W, von Deimling A, et al. Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas. Cell Reports. Medicine. 4: 101249. PMID 37883975 DOI: 10.1016/j.xcrm.2023.101249  0.699
2022 Demirdizen E, Al-Ali R, Narayanan A, Sun X, Varga JP, Steffl B, Brom M, Krunic D, Schmidt C, Schmidt G, Bestvater F, Taranda J, Turcan Ş. TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing. Neuro-Oncology. PMID 36215168 DOI: 10.1093/neuonc/noac233  0.707
2022 Schönrock A, Heinzelmann E, Steffl B, Demirdizen E, Narayanan A, Krunic D, Bähr M, Park JW, Schmidt C, Özduman K, Pamir MN, Wick W, Bestvater F, Weichenhan D, Plass C, et al. MEOX2 homeobox gene promotes growth of malignant gliomas. Neuro-Oncology. PMID 35468210 DOI: 10.1093/neuonc/noac110  0.705
2021 Taranda J, Turcan S. 3D Whole-Brain Imaging Approaches to Study Brain Tumors. Cancers. 13. PMID 33920839 DOI: 10.3390/cancers13081897  0.691
2020 Narayanan A, Blanco-Carmona E, Demirdizen E, Sun X, Herold-Mende C, Schlesner M, Turcan S. Nuclei Isolation from Fresh Frozen Brain Tumors for Single-Nucleus RNA-seq and ATAC-seq. Journal of Visualized Experiments : Jove. PMID 32925882 DOI: 10.3791/61542  0.338
2020 Wang Y, Wild AT, Turcan S, Wu WH, Sigel C, Klimstra DS, Ma X, Gong Y, Holland EC, Huse JT, Chan TA. Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. Science Advances. 6: eaaz3221. PMID 32494639 DOI: 10.1126/Sciadv.Aaz3221  0.343
2018 Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, ... ... Turcan S, et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nature Medicine. PMID 29988124 DOI: 10.1038/S41591-018-0095-6  0.333
2018 Cahill D, Turcan S. Origin of Gliomas. Seminars in Neurology. 38: 5-10. PMID 29548046 DOI: 10.1055/S-0037-1620238  0.318
2017 Turcan S, Makarov V, Taranda J, Wang Y, Fabius AWM, Wu W, Zheng Y, El-Amine N, Haddock S, Nanjangud G, LeKaye HC, Brennan C, Cross J, Huse JT, Kelleher NL, et al. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nature Genetics. PMID 29180699 DOI: 10.1038/S41588-017-0001-Z  0.716
2015 Walsh LA, Roy DM, Reyngold M, Giri D, Snyder A, Turcan S, Badwe CR, Lyman J, Bromberg J, King TA, Chan TA. RECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switch. Oncogene. 34: 2189-203. PMID 24931164 DOI: 10.1038/Onc.2014.175  0.33
2015 Danussi C, Bose P, Parthasarathy P, Turcan S, Picketts D, Chan T, Huse J. Epig-06Atrx Deficiency Promotes Migratory Behavior In Glioma Cells Of Origin By Dysregulating Genome-Wide Chromatin Accessibility And Modulating Transcriptional Programs. Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov214.06  0.382
2014 Gong Y, Zack TI, Morris LG, Lin K, Hukkelhoven E, Raheja R, Tan IL, Turcan S, Veeriah S, Meng S, Viale A, Schumacher SE, Palmedo P, Beroukhim R, Chan TA. Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nature Genetics. 46: 588-94. PMID 24793136 DOI: 10.1038/Ng.2981  0.327
2013 Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, Chan TA. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget. 4: 1729-36. PMID 24077826 DOI: 10.18632/Oncotarget.1412  0.376
2013 Borodovsky A, Salmasi V, Turcan S, Fabius AW, Baia GS, Eberhart CG, Weingart JD, Gallia GL, Baylin SB, Chan TA, Riggins GJ. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget. 4: 1737-47. PMID 24077805 DOI: 10.18632/Oncotarget.1408  0.331
2013 Tönjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, Pleier SV, Bai AH, Karra D, Piro RM, Felsberg J, Addington A, Lemke D, Weibrecht I, Hovestadt V, ... ... Turcan S, et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nature Medicine. 19: 901-8. PMID 23793099 DOI: 10.1038/Nm.3217  0.336
2013 Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, Ramaswami D, Walsh LA, Eng S, Huse JT, Zhang J, Dolgalev I, Huberman K, Heguy A, Viale A, ... ... Turcan S, et al. The mutational landscape of adenoid cystic carcinoma. Nature Genetics. 45: 791-8. PMID 23685749 DOI: 10.1038/Ng.2643  0.315
2013 Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (New York, N.Y.). 340: 626-30. PMID 23558169 DOI: 10.1126/Science.1236062  0.335
2013 Agarwal M, Nitta R, Dovat S, Li G, Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, ... ... Turcan S, et al. CELL BIOLOGY AND SIGNALING Neuro-Oncology. 15: iii12-iii31. DOI: 10.1093/Neuonc/Not174  0.325
2012 Basappa J, Graham CE, Turcan S, Vetter DE. The cochlea as an independent neuroendocrine organ: expression and possible roles of a local hypothalamic-pituitary-adrenal axis-equivalent signaling system. Hearing Research. 288: 3-18. PMID 22484018 DOI: 10.1016/J.Heares.2012.03.007  0.718
2012 Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 483: 474-8. PMID 22343901 DOI: 10.1038/Nature10860  0.305
2012 Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 483: 479-83. PMID 22343889 DOI: 10.1038/Nature10866  0.306
2011 Graham CE, Basappa J, Turcan S, Vetter DE. The cochlear CRF signaling systems and their mechanisms of action in modulating cochlear sensitivity and protection against trauma. Molecular Neurobiology. 44: 383-406. PMID 21909974 DOI: 10.1007/S12035-011-8203-3  0.717
2011 Turcan S, Vetter DE, Maron JL, Wei X, Slonim DK. Mining functionally relevant gene sets for analyzing physiologically novel clinical expression data. Pacific Symposium On Biocomputing. Pacific Symposium On Biocomputing. 50-61. PMID 21121032  0.59
2010 Basappa J, Turcan S, Vetter DE. Corticotropin-releasing factor-2 activation prevents gentamicin-induced oxidative stress in cells derived from the inner ear. Journal of Neuroscience Research. 88: 2976-90. PMID 20544827 DOI: 10.1002/Jnr.22449  0.725
2010 Turcan S, Slonim DK, Vetter DE. Lack of nAChR activity depresses cochlear maturation and up-regulates GABA system components: temporal profiling of gene expression in alpha9 null mice. Plos One. 5: e9058. PMID 20140217 DOI: 10.1371/Journal.Pone.0009058  0.656
2009 Vetter DE, Basappa J, Turcan S. Multiplexed isobaric tagging protocols for quantitative mass spectrometry approaches to auditory research. Methods in Molecular Biology (Clifton, N.J.). 493: 345-66. PMID 18839358 DOI: 10.1007/978-1-59745-523-7_21  0.69
2007 Vetter DE, Katz E, Maison SF, Taranda J, Turcan S, Ballestero J, Liberman MC, Elgoyhen AB, Boulter J. The alpha10 nicotinic acetylcholine receptor subunit is required for normal synaptic function and integrity of the olivocochlear system. Proceedings of the National Academy of Sciences of the United States of America. 104: 20594-9. PMID 18077337 DOI: 10.1073/Pnas.0708545105  0.708
Low-probability matches (unlikely to be authored by this person)
2019 Venkataramani V, Tanev D, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, Losada Perez M, Körber C, Kardorff M, Ratliff M, Xie R, Horstmann H, Messer M, Paik S, Knabbe J, ... ... Turcan S, et al. TMIC-27. GLUTAMATERGIC NEURON-GLIOMA SYNAPSES DRIVE BRAIN TUMOUR PROGRESSION Neuro-Oncology. 21: vi253-vi253. DOI: 10.1093/Neuonc/Noz175.1061  0.296
2014 Silber J, Harinath G, Parthasarathy PT, Fabius AWM, Turcan S, Chan TA, Huse JT. Abstract 521: Glioma-associated IDH mutation induces miR-34a repression and stem cell-like physiology through enhanced PDGF signaling Cancer Research. 74: 521-521. DOI: 10.1158/1538-7445.Am2014-521  0.295
2016 Danussi C, Bose P, Parthasarathy P, Silberman P, Turcan S, Picketts D, Chan T, Huse J. Gent-21. Atrx Deficiency Promotes Invasion And Alters The Differentiation Capacity Of Glioma Cells Of Origin By Dysregulating Genome-Wide Chromatin Accessibility And Modulating Transcriptional Programs Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.327  0.292
2019 Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, Körber C, Kardorff M, Ratliff M, Xie R, Horstmann H, Messer M, Paik SP, Knabbe J, Sahm F, ... ... Turcan S, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. PMID 31534219 DOI: 10.1038/S41586-019-1564-X  0.286
2015 Bai H, Harmancı AS, Erson-Omay EZ, Li J, Coşkun S, Simon M, Krischek B, Özduman K, Omay SB, Sorensen EA, Turcan Ş, Bakırcığlu M, Carrión-Grant G, Murray PB, Clark VE, et al. Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nature Genetics. PMID 26618343 DOI: 10.1038/Ng.3457  0.271
2013 Ho AS, Turcan S, Chan TA. Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. Oncotargets and Therapy. 6: 223-32. PMID 23569385 DOI: 10.2147/Ott.S34680  0.266
2011 Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, Baylin SB, Ahuja N, Viale A, Massague J, Norton L, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Science Translational Medicine. 3: 75ra25. PMID 21430268 DOI: 10.1126/Scitranslmed.3001875  0.245
2014 Gerber NK, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K, Beal K, Omuro A, Yamada Y, Gutin P, Brennan CW, Huse JT, Chan TA. Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncology. 16: 1186-95. PMID 24662514 DOI: 10.1093/Neuonc/Nou043  0.239
2013 Turcan S, Chan TA. MAPping the genomic landscape of low-grade pediatric gliomas. Nature Genetics. 45: 847-9. PMID 23892663 DOI: 10.1038/Ng.2706  0.239
2014 Reyngold M, Turcan S, Giri D, Kannan K, Walsh LA, Viale A, Drobnjak M, Vahdat LT, Lee W, Chan TA. Remodeling of the methylation landscape in breast cancer metastasis. Plos One. 9: e103896. PMID 25083786 DOI: 10.1371/Journal.Pone.0103896  0.236
2020 Narayanan A, Turcan S. The Magnifying GLASS: Longitudinal Analysis of Adult Diffuse Gliomas. Cell. 180: 407-409. PMID 32032515 DOI: 10.1016/J.Cell.2020.01.016  0.235
2023 Park JW, Kilic O, Deo M, Jimenez-Cowell K, Demirdizen E, Kim H, Turcan Ş. CIC reduces xCT/SLC7A11 expression and glutamate release in glioma. Acta Neuropathologica Communications. 11: 13. PMID 36647117 DOI: 10.1186/s40478-023-01507-y  0.214
2016 Oktay Y, Ülgen E, Can Ö, Akyerli CB, Yüksel Ş, Erdemgil Y, Durası IM, Henegariu OI, Nanni EP, Selevsek N, Grossmann J, Erson-Omay EZ, Bai H, Gupta M, Lee W, et al. IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation. Scientific Reports. 6: 27569. PMID 27282637 DOI: 10.1038/Srep27569  0.201
2019 Al-Ali R, Bauer K, Park JW, Al Abdulla R, Fermi V, von Deimling A, Herold-Mende C, Mallm JP, Herrmann C, Wick W, Turcan Ş. Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas. Acta Neuropathologica Communications. 7: 201. PMID 31806013 DOI: 10.1186/s40478-019-0851-y  0.196
2019 Park JW, Turcan Ş. Epigenetic Reprogramming for Targeting -Mutant Malignant Gliomas. Cancers. 11. PMID 31652645 DOI: 10.3390/cancers11101616  0.18
2022 Haddock S, Alban TJ, Turcan Ş, Husic H, Rosiek E, Ma X, Wang Y, Bale T, Desrichard A, Makarov V, Monette S, Wu W, Gardner R, Manova K, Boire A, et al. Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells. Neoplasia (New York, N.Y.). 28: 100790. PMID 35398668 DOI: 10.1016/j.neo.2022.100790  0.178
2022 von Knebel Doeberitz N, Paech D, Sturm D, Pusch S, Turcan S, Saunthararajah Y. Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas. International Journal of Cancer. PMID 35603902 DOI: 10.1002/ijc.34131  0.166
2023 Cui H, Sun X, Schilling M, Herold-Mende C, Reischl M, Levkin PA, Popova AA, Turcan Ş. Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip. Advanced Healthcare Materials. e2300591. PMID 37162029 DOI: 10.1002/adhm.202300591  0.164
2021 Sun X, Turcan S. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. Cells. 10. PMID 34067729 DOI: 10.3390/cells10051225  0.16
2020 Park JW, Sahm F, Steffl B, Arrillaga-Romany I, Cahill D, Monje M, Herold-Mende C, Wick W, Turcan Ş. TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. Neuro-Oncology. PMID 32882013 DOI: 10.1093/Neuonc/Noaa207  0.158
2021 Fresnais M, Turcan S, Theile D, Ungermann J, Abou Zeed Y, Lindner JR, Breitkopf M, Burhenne J, Haefeli WE, Longuespée R. Approaching Sites of Action of Temozolomide for Pharmacological and Clinical Studies in Glioblastoma. Biomedicines. 10. PMID 35052681 DOI: 10.3390/biomedicines10010001  0.135
2017 Walsh LA, Alvarez MJ, Sabio EY, Reyngold M, Makarov V, Mukherjee S, Lee KW, Desrichard A, Turcan Ş, Dalin MG, Rajasekhar VK, Chen S, Vahdat LT, Califano A, Chan TA. An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis. Cell Reports. 20: 1623-1640. PMID 28813674 DOI: 10.1016/J.Celrep.2017.07.052  0.131
2022 Liang Y, Turcan S. Epigenetic Drugs and Their Immune Modulating Potential in Cancers. Biomedicines. 10. PMID 35203421 DOI: 10.3390/biomedicines10020211  0.125
2023 Fresnais M, Jung I, Klein UB, Miller AK, Turcan S, Haefeli WE, Burhenne J, Longuespée R. Important Requirements for Desorption/Ionization Mass Spectrometric Measurements of Temozolomide-Induced 2'-Deoxyguanosine Methylations in DNA. Cancers. 15. PMID 36765673 DOI: 10.3390/cancers15030716  0.108
2023 Turcan Ş. SIRT2 inhibition as the Achilles' heel of ATRX-deficient gliomas. Neuro-Oncology. PMID 37941518 DOI: 10.1093/neuonc/noad217  0.095
2021 Opitz CA, Turcan S. From anti-aging drugs to cancer therapy: is there a potential for sirtuin activators in gliomas? Neuro-Oncology. 23: 3-5. PMID 33059365 DOI: 10.1093/neuonc/noaa234  0.057
Hide low-probability matches.